STAREE Trial: Atorvastatin Cuts Major CV Events by 30% in Older Adults, Driven Mainly by Nonfatal Events - Medscape

STAREE Trial: Atorvastatin Cuts Major CV Events by 30% in Older Adults, Driven Mainly by Nonfatal Events - Medscape
Health

Listen to this article

0%

MUNICH — Atorvastatin reduced the risk of major cardiovascular (CV) events, predominantly nonfatal events, by 30% compared with placebo in adults aged 70 years or older without known cardiovascular d… [+8140 chars]

Leave A Comment

Comments are moderated and may take time to appear.

Comments

No comments yet. Be the first to comment!

Stay Connected